Le Lézard
Classified in: Environment, Health
Subjects: SVY, ENI

airPHX Validates Technology for Eliminating Pathogens on Surfaces in Health Care Facilities


MCLEAN, Va., Nov. 14, 2017 /PRNewswire/ -- airPHX ("air fix") announces independent research confirming the effectiveness of airPHX technology in eliminating three common healthcare-associated infection (HAI) pathogens.  The research, conducted by Rick Falkenberg, Ph.D with Scientific Air Solutions and published September 13, 2017, demonstrates over 4-log reductions in 30 minutes of treatment in bacterial populations of Clostridium difficile, Methicillin Resistant Staphylococcus aureus (mRSA) and Pseudomonas aeruginosa on three common contact surfaces: stainless steel, plastic (PVC) and linoleum (floor tile).  Each bacterial population exhibited in excess of 5-log reductions in organisms in 2 hours of treatment.  The research can be reviewed at https://www.airPHXhealth.com/blog

Effective on both airborne and surface pathogens, airPHX technology provides continuous infection control for the health care industry.  Using a proprietary application of atmospheric cold plasma, airPHX offers a cost-effective alternative to existing infection control protocols.  Scalable and affordable... airPHX has been proven effective on 30 common HAI pathogens including bacteria, viruses and protozoa.

Antimicrobial resistant pathogens pose an ongoing challenge to hospitals because they cause HAIs during clinical treatment of patients. Existing methods to address this challenge include sanitizers/disinfectants and deployment of UV-C technology. Both solutions have limitations and neither solution provides ongoing protection between treatments.

airPHX technology operates continuously in the background as a prophylaxis with no labor costs and minimal operating expenses.  airPHX uses a proprietary atmospheric cold plasma technology to create and distribute a low-level, unique spectrum of reactive oxygen species (ROS).  The ROS operate as an oxidizer of pathogens in a treatment space, persistently eliminating airborne and surface pathogens in the air and on all surfaces exposed to ambient air. 

According to Dr. Falkenberg: "the technology developed by airPHX has a wide range of applications due to its ability to produce a highly oxidative environment within a reaction chamber and discharge molecules that have an oxidizing capacity at levels that are safe for human exposure into the environment."  

airPHX technology has previously been commercialized for large facilities in food safety applications. Adapting the technology for the health care industry was a natural progression.  Deployed in hospitals, medical device storage, senior care, athletic facilities and other health facilities, airPHX technology provides immediate and continuing infection control at low capital and operating costs.

For complete information on the airPHX system and research results, please visit: www.airPHXhealth.com.

About airPHX | HEALTH

airPHX is a private company offering air and surface sanitization solutions. It is known for its cost-effective and innovative technology that delivers results without the usage of chemicals or UV radiation.

SOURCE airPHX


These press releases may also interest you

at 02:54
HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature...

at 02:50
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany?Universitätsklinikum Tübingen...

at 02:24
Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ('SciBase' or the 'Company') rights issue of units of up to approximately SEK 15 million commences (the 'Rights Issue'). The Rights Issue was resolved by the Board of...

at 02:05
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A...

at 02:00
Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan. Participants of this round are: Beyond Next Ventures Inc.The University of Tokyo Edge Capital Partners Co., Ltd.Keio...

at 01:05
Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care...



News published on and distributed by: